{
    "id": "799ef4b7-9e29-46e8-b0d1-78fd9e404144",
    "indications": {
        "text": "ojemda indicated treatment patients 6 months age older relapsed refractory pediatric low-grade glioma ( lgg ) harboring braf fusion rearrangement , braf v600 mutation . indication approved accelerated approval based response rate duration response [ ( 14 ) ] . continued approval indication may contingent upon verification description benefit confirmatory trial ( ) .",
        "doid_entities": [
            {
                "text": "pediatric low-grade glioma (DOID:0080830)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0080830"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "confirm presence braf fusion rearrangement , braf v600 mutation prior initiation treatment ojemda . ( 2.1 ) recommended ojemda based body surface area ( tables 1 2 ) . ( 2.3 ) administer ojemda orally , weekly , without food . ( 2.3 , 2.4 ) . tablets : swallow tablets whole water . chew , cut , crush . ( 2.4 ) oral suspension : full prescribing information preparation instructions . ( 2.4 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "adverseReactions": "none .",
    "ingredients": [
        {
            "name": "TOVORAFENIB",
            "code": "ZN90E4027M",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15266"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "COPOVIDONE K25-31",
            "code": "D9C330MD8B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_78913"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        }
    ],
    "organization": "Day One Biopharmaceuticals, Inc.",
    "name": "OJEMDA",
    "effectiveTime": "20250501",
    "indications_original": "OJEMDA is indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.\n                  This indication is approved under accelerated approval based on response rate and duration of response [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contraindications_original": "Confirm the presence of BRAF fusion or rearrangement, or BRAF V600 mutation prior to initiation of treatment with OJEMDA. ( 2.1 ) Recommended dosage of OJEMDA is based on body surface area ( see Tables 1 and 2 ). ( 2.3 ) Administer OJEMDA orally, once weekly, with or without food. ( 2.3 , 2.4 ). Tablets : Swallow tablets whole with water. Do not chew, cut, or crush. ( 2.4 ) For Oral Suspension : See full prescribing information for preparation and administration instructions. ( 2.4 )",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "OJEMDA",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15266"
        }
    ]
}